Breaking News

Quintiles Invests in Biomarker Research Startup

Will have strategic partnership with Quintiles Consulting and Quintiles Global Laboratories

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Quintiles has invested in a new company, Oxford Cancer Biomarkers, formed to provide oncology consulting services and new cancer biomarkers. The company will develop biomarkers using CancerNav, a DNA- and protein-based assay technology platform invented by Nick La Thangue, Ph.D., chair of Cancer Biology at Oxford University. David Kerr, CBE, DSc, M.D, FMedSci., professor of Cancer Medicine at the University of Oxford, will serve as the new company’s chief medical officer. Quintiles is the large...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters